- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Tocilizumab for relapsing and remitting giant cell arteritis: a case series ; volume:16 ; number:1 ; day:27 ; month:10 ; year:2022 ; pages:1-10 ; date:12.2022
Journal of medical case reports ; 16, Heft 1 (27.10.2022), 1-10, 12.2022
- Creator
-
Saha, Pratyasha
Srikantharajah, Denesh
Kaul, Arvind
Sofat, Nidhi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13256-022-03625-y
- URN
-
urn:nbn:de:101:1-2023010421090472824722
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Saha, Pratyasha
- Srikantharajah, Denesh
- Kaul, Arvind
- Sofat, Nidhi
- SpringerLink (Online service)
Other Objects (12)
Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Relapsing/remitting type 1 diabetes
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Serum prolactin in patients with relapsing remitting multiple sclerosis
Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Relapsing/remitting type 1 diabetes
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Serum prolactin in patients with relapsing remitting multiple sclerosis
Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Relapsing/remitting type 1 diabetes
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Serum prolactin in patients with relapsing remitting multiple sclerosis
Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis